Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

NCT05581303 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05581303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05581303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 14, 2022
Completion date
March 31, 2028
Enrollment
7,297 (actual)
Sites
737

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease